A randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancerA. T. Shaw,T. M. Bauer, T. Takahashi,C. S. Baik,A. Polli,M. Carpentieri,J-F. Martini,B. J. SolomonAnnals of Oncology（2017）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
